Anavex Life Sciences, a clinical-stage biopharmaceutical
company, has announced encouraging results from its 48-week Phase 2 extension
study of ANAVEX®2-73 (blarcamesine) in patients with Parkinson’s disease
dementia. This open-label study highlights significant improvements across
multiple efficacy endpoints, signaling a promising advance in treating
neurodegenerative disorders.
The study, designated as ANAVEX2-73-PDD-EP-001, assessed the safety, tolerability, and
efficacy of ANAVEX®2-73 over a 48-week period. Participants showed marked
enhancements in clinical symptoms, as evidenced by the Movement Disorder
Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and the Clinical
Global Impression – Improvement (CGI-I) scores.
Dr. Christopher U Missling, President & CEO of Anavex, stated, “It is encouraging that
patients’ clinical symptoms consistently improved longitudinally during the
extension phase under active ANAVEX®2-73 treatment. This data suggests
ANAVEX®2-73’s potential capability to slow and potentially reverse the
life-altering symptoms of Parkinson’s disease.”
Anavex is preparing to move forward with a pivotal 6-month Parkinson’s disease study, bolstered by these
preliminary Phase 2 findings. The company aims to further establish the
efficacy and safety profile of ANAVEX®2-73 in a larger patient population.
Furthermore, the Michael J. Fox Foundation (MJFF) has awarded Anavex a research grant to fund an imaging-focused Parkinson’s disease
clinical trial with ANAVEX®2-73. This grant underscores the significant
therapeutic potential of ANAVEX®2-73 in addressing the urgent unmet needs of
Parkinson’s disease patients.
Anavex Life Sciences continues to push the boundaries in the development of novel
therapeutics for neurodegenerative and neurodevelopmental disorders. With its
flagship product, ANAVEX®2-73, the company is making strides towards offering
new hope to patients suffering from debilitating conditions like Parkinson’s
and Alzheimer’s disease. See related link for more information.
For more information, visit the Anavex Life Sciences website.
Learn more about Anavex on https://finance.yahoo.com/quote/AVXL/